Eric Trump

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Space-Eyes’ planned $638 million Nasdaq merger with McKinley Acquisition Corporation puts the defence technology company’s counter-drone systems, future CUAS ticker and ambitious contract-growth strategy under investor scrutiny. Representative image.

Space-Eyes lines up $638m Nasdaq debut via McKinley SPAC as Eric Trump joins as strategic adviser

Space-Eyes agrees $638M Nasdaq listing via McKinley SPAC with Eric Trump advising, on $1M revenue and a $35M pipeline. Can contract conversion close the gap?

byVenkatesh

August 1, 2026

Trump’s $10bn IRS lawsuit faces new court challenge over presidential control

Federal judge orders Trump and Department of Justice to justify why his $10 billion Internal Revenue Service lawsuit should proceed.

byVenkatesh

April 25, 2026

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Space-Eyes lines up $638m Nasdaq debut via McKinley SPAC as Eric Trump joins as strategic adviser

Trump’s $10bn IRS lawsuit faces new court challenge over presidential control

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?